Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual Report

About this update from Shandong Lukang Pharmaceutical Co., Ltd. Class A

Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual ReportThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shandong Lukang Pharmaceutical Co., Ltd. Class A